COMMENT. This prospective study shows that primary infection with HHV-6 or -7 is responsible for encephalopathy and/or severe convulsions with fever in 17% of children <2 years of age (median age 1 year) who require hospitalization. Primary HHV infection is not associated with the rash of exanthem subitum in one half the cases. CSF does not show evidence of direct viral involvement of the CNS, and the severe convulsions with fever could be classified as "complex febrile seizures." In the US, infection with HHV-6 accounts for one-third of all first-time febrile seizures in children <2 years old (Hall, Epstein, et al. N Engl J Med 1994;331:432-438; Ped Neur Briefs 2004; 18:59). An elevated cytokine response independent of the severity of infection may be a factor in the mechanism of febrile seizures (Kawada et al, 2003; Millichap JG, Millichap JJ. J Infect Dis 2003; 189:564).
Cytokines and febrile seizures. The height of the fever (not rate of rise) is the important determinant of a threshold to febrile seizures (Millichap, JG. Pediatrics 1959; 23:76-85 
ATTENTION DEFICIT HYPERACTIVITY DISORDER LONG-TERM EFFECTS OF ADBERALL XR IN ADHD
The long-term tolerability and effectiveness of extended release mixed amphetamine salts (Adderall XR) in children with attention deficit hyperactivity disorder (ADHD) were evaluated in a 24-month, multicenter, open-label extension of 2 placebo-controlled studies at UCLA, Massachusetts General Hospital, UC-Irvine, Maitland, FL, and Shire Pharmaceutical, Wayne, PA. The initial dose of Adderall XR was 10 mg daily in 568 children, aged 6-12 years, and was increased by 10 mg weekly to optimal effective levels (maximum 30 mg/d). Quarterly Conners Global Index Scale, Parent version (CGIS-P) was used to assess effectiveness, and adverse events, physical examinations, and laboratory tests were monitored to assess tolerability. Significant improvements (>30%, p<0.001) in CGIS-P scores were maintained through the trial, and treatment was generally well tolerated. Adverse events (AE) included headache (15%), anorexia (15%), and insomnia (11%); 15% withdrew from the study because of AE (weight loss, anorexia, insomnia, depression, and emotional lability). Serious AE were reported in 18 subjects (3%); only 2, both convulsions, were judged possibly drug-related, at doses of 10 and 20 mg/d. None required subsequent treatment with anticonvulsants. Mean systolic blood pressure increased by 3. COMMENT. This paper is something of a cliff-hanger. The promise of a second installment in a subsequent publication is frustrating. The effectiveness and general tolerability of Adderall XR is well known, but answers to the concerns regarding cardiovascular events are anxiously awaited. Hopefully, we can expect this report soon.
Atomoxetine-induced blood pressure increase. A significant elevation in blood pressure is noted in 3 adolescent boys while taking doses of 80 mg/day atomoxetine (Dworkin N. J Am Acad Child Adolesc Psychiatry June 2005;44:510). Other drugs were given in combination, compromising the significance of the report, but our own practice of monitoring BP, pulse, height, and weight regularly in ADHD patients will be continued.
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